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Abstract
Matrix metalloproteinases (MMPs) are a subfamily of zinc-dependent proteases that are re-sponsible for degradation and remodeling of extracellular matrix proteins. The activity of MMPs is tightly regulated at several levels including cleavage of prodomain,
allosteric activation, com-partmentalization and complex formation with tissue inhibitor of metalloproteinases (TIMPs). In the
central nervous system (CNS), MMPs play a wide variety of roles ranging from brain devel-opment, synaptic plasticity and repair
after injury to the pathogenesis of various brain disorders. Following general discussion on the domain structure and the regulation of activity of MMPs, we emphasize their implication in various brain disorder conditions such as Alzheimer’s disease, multiple
sclerosis, ischemia/reperfusion and Parkinson’s disease. We further highlight accumu-lating evidence that MMPs might be the
culprit in Parkinson’s disease (PD). Among them, MMP-3 appears to be involved in a range of pathogenesis processes in PD
including neuroinflamma-tion, apoptosis and degradation of α-synuclein and DJ-1. MMP inhibitors could represent poten-tial novel
therapeutic strategies for treatments of neurodegenerative diseases.
Key Words: Matrix metalloproteinases, MMP-3, Parkinson’s disease, Microglia, Neurodegenerative disorders

The matrix metalloproteinases (MMPs) are zinc and calcium-dependent endopeptidases which belong to the metzincin
superfamily like the astacins, serralysins, reprolysins, and
adamalysins or disintegrin metalloproteinases (ADAMs).
Since its first discovery by Jerome Gross and Charles Lapiere
in 1962 (Gross and Lapiere, 1962), MMPs have constituted
a large family of pro-teases. Currently, 24 MMP genes and
23 MMP proteins have been reported because two iden-tical
genes in chromosome 1 encode MMP-23. They are a group
of proteolytic enzymes that are involved in degradation and
remodeling of extracellular matrix (ECM) and basement membrane proteins. Accumulating evidence, however, suggests
that MMPs are also participating in a range of physiological
processes such as inflammation, immunity, neurite growth
and bone remodeling through processing bioactive molecules
including cell surface receptors, apoptotic ligands, pro-neurotrophic factors and chemokines/cytokines (Yamamoto et al.,
1999; Lee et al., 2001; Van Lint and Libert, 2007).
In the central nervous system (CNS), MMPs play a fundamental role in CNS development in-cluding neurogenesis,
myelogenesis, and axonal guidance as well as maintaining
normal brain functions such as synaptic plasticity, learning
and memory. The basic biology and roles of MMPs in the CNS

have been extensively discussed by recent reviews (Yong,
2005; Agrawal et al., 2008). In this review, we provide an
overview of the basic biochemical characteristics, regulation
of activation and biological functions of MMPs, and then discuss their role in the CNS mainly focusing on brain pathologic
conditions including neurodegeneration, neuroinflammation
and ischemia.
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MODULAR DOMAIN STRUCTURE AND SUBFAMILIES
The MMP members share structural homologies including common N-terminal propeptide and catalytic domains. In
addition, subfamilies are categorized by other domains such
as fibro-nectin-like repeats, C-terminal hemopexin-like domains, Ig-like domain and transmembrane domains (Fig. 1).
All MMPs have an N-terminal signal peptide directing them
to the secretory pathway. Except membrane-type MMPs (MTMMPs), all MMPs are destined to be released into the extracellular space as inactive pro-enzyme forms called zymogens.
The propeptide domain, consisting of about 80 amino acids,
has a conserved PRCG (V/N)PD amino acid sequence. The
cysteine contained within this sequence interacts with zinc
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Fig. 1. Domain structure of matrix metalloproteinases family. All MMPs consist of a N-terminal signal peptide and a propeptide domain fol-

lowed by a C-terminal catalytic domain. A propeptide domain contains a cysteine switch which forms complex with catalytic zinc in a catalytic domain inhibiting their enzymatic activity. MMP-7 and -26 have only the minimal domain. Most of MMPs have a linker (hinge-region) and
hemopexin like do-main at the C-terminal to a catalytic domain. MMP-11, -21 and -28 have a furin-activating motif, RX[K/R]R, at the C-terminal end of their propeptide domains. Two gelatinases, MMP-2 and -9, contain three fibronectin II like repeats in the catalytic domains. MMP9 is the only MMP which has a heavily O-glycosylated hinge region. All membrane-anchored MMPs contain a furin-activating motif. MT4, -6MMPs are anchored to the plasma membrane through GPI-anchor. MT1, -2, -3 and-5-MMPs are bound to the cell membrane through type
I transmembrane domain while MMP-23 is through type II transmembrane domain. The C-terminal of MMP-23 contains cysteine array (Ca)
and immunoglobulin (Ig)-like domain replacing hemopexin domain.

in the catalytic domain to suppress its own proteolytic activity (Cysteine-switch) (Van Wart and Birkedal-Hansen, 1990;
Becker et al., 1995). The catalytic domain consisting of about
160-170 amino acids has a HEXXHXXGXXH, catalytic zincbinding motif and a conserved methionine, which form a
unique “Met-turn” struc-ture (Bode et al., 1993). The catalytic
domain also requires an additional structural zinc and 2 to 3
calcium ions for the stability and the enzymatic activity. MMP-7
and -26 consist of this minimal domain, propeptide and catalytic domains. C-terminal structures after catalytic domains
are much more variable conferring MMPs substrate specificity
and the interface for interaction with TIMPs (tissue inhibitor of
metalloproteinases). Most MMPs have a linker (hinge region)
and a hemopexin-like domain in addition to a minimal domain.
The hinge region of most MMPs consists of 10-30 amino acids that connects a catalytic domain and a hemopexin-like domain. C-terminus hemopexin domain in collagenase (MMP-1,
interstitial collagenase) is crucial for cleavage of triple helical
interstitial collagen (Bode, 1995). The two gelatinases (MMP-2
and MMP-9) have additional three fibronectin-like repeats in
their catalytic domain that interact with collagens and gelatins,
respectively (Allan et al., 1995; Steffensen et al., 1995). Additionally, MMP-9 has a heavily O-glycosylated hinge region that
is responsible for fine tuning its bioavailability (Van den Steen
et al., 2006). The membrane-type MMP subfamily has a transmembrane domain that anc-hors MMPs to the cell surface.

http://dx.doi.org/10.4062/biomolther.2012.20.2.133

MT1 through 6-MMPs and MMP23 belong to this subfamily.
Three secreted MMPs (MMP-11, -21, -28) and all MT-MMPs
have a basic RX[K/R]R motif at the C-terminal end of propeptide domain which can be cleaved by intracellular furin.

Regulation of MMPs
Since MMPs are able to degrade all the protein constituents in the extracellular matrix, their pro-teolytic activity has to
be tightly controlled under normal conditions to prevent tissue
destruction (Yong et al., 1998). There are the following ways
to regulate the activity of MMPs: 1) gene tran-scriptional regulation; 2) activation of proenzyme by removing the propeptide
domain; 3) the in-teraction with tissue inhibitor of metalloproteinases (TIMPs); 4) pericellular or intracellular com-partmentalization; 5) allosteric activation; 6) oxidative modification.
Many MMP genes are inducible by a wide variety of effectors
including growth factors, cytokines such as TNF-α and IL-1β,
chemical agents, physical stress, oncogen products and interestingly, cell-cell or cell-ECM inte-raction (Ries and Petrides,
1995; Vincenti, 2001; Vincenti and Brinckerhoff, 2007). Their
gene ex-pression also can be suppressed by other factors
such as TGF-β, retinoic acids and glucocorti-coids (Osteen
et al., 1996; Li et al., 2011; Ye et al., 2011). These external
effectors trigger the var-ious intracellular signal transduction
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pathways including MAPKs, JAK-STAT or NF-κB pathways
leading to the induction of MMP genes (Korzus et al., 1997;
Kheradmand et al., 1998; Reunanen et al., 1998). Although
the activator protein-1 (AP-1) binding site in the MMP promoters has been considered as a main transcriptional regulator in
most MMPs (Auble and Brinckerhoff, 1991; Kim et al., 2008;
Liu et al., 2010; Singh et al., 2010), MMP-8, -11 and -21 are
lack of AP-1 cis-element in their promoter. Another group of
promoters of MMP-2, -14, and -28 does not have TATA box
and are mainly regulated by ubiquitous Sp-1 family of transcriptional factor (Yan and Boyd, 2007).
The MMPs are initially expressed as inactive zymogens
in which a zinc atom in the catalytic domain interacts with a
cysteine residue (Cysteine switch) (Van Wart and BirkedalHansen, 1990). Activating factors cause the disruption of the
Cys-Zn2+ interaction, which renders pro-MMPs par-tially active. Then, the partially active enzyme auto-catalyzes the propeptide region and make the enzyme fully active (Van Wart
and Birkedal-Hansen, 1990). Activation of all MT-MMPs and
furin-activated MMPs is well characterized intracellular event
which leads to immediate catalytic activation of MMPs upon
appearing on the cell surface or secretion. This process is
achieved by serine proteinase, furin that is localized in the
trans-Golgi network. Remaining MMPs are se-creted as inactive zymogens and activated by serine proteinases like
plasmin or other MMPs (MMP-3 and -14). Plasmin that is activated from plasminogen by the action of tissue- or urokinaseplasminogen activator is an important physiologic activator of
pro-MMPs. Activation of proMMP could be achieved without
involving proteolytic cleavage of prodomain by the mechanism
called allosteric activation. Both proMMP-9 and -2 could be
activated upon binding to their substrates, gelatin or collagen
IV and α2 chain of collagen VI, respectively (Bannikov et al.,
2002; Freise et al., 2009). Reactive oxygen species (ROS),
peroxynitrite, glutathione could activate MMPs without removal of prodomains through modification of thiol in their catalytic
core which lead to disruption of thiol-zinc interaction (Okamoto
et al., 2001; Gu et al., 2002; McCarthy et al., 2008).
Tissue inhibitors of metalloproteinases (TIMPs) are the endogenous regulators of MMP activ-ities in the tissue (Vincenti,
2001). Following activation, the activities of MMPs are regulated by the formation of non-covalent complexes with TIMPs.
Four homologous TIMPs have been iden-tified to date (Yong
et al., 1998). They have about 190 amino acids with longer
N-terminal and shorter C-terminal domain. N-terminal domain
itself is fully functional in terms of inhibition of MMPs by chelating their catalytic zinc atom. The expression of TIMPs is also
regulated at the transcriptional level. For example, TIMP-1
contains AP-1 site in its promoter (Ulisse et al., 1994). This
implies that the expression of MMPs and TIMPs can be regulated coordinately by the same signal. However, the MMPs
and TIMPs can also be regulated in opposite patterns. It has
been shown that TGF-β induces the increased expression of
TIMP-1 and suppresses collagenase and stromelysin (MMP3) expression in fibroblasts and endothelial cells (Edwards et
al., 1987). Since a number of studies have demonstrated that
excessive production of MMPs are involved in the pathology
of many inflammatory and malignant diseases, the balance
between the MMPs and their inhibitors is thought to be important in the maintenance of normal physiologic conditions.

Accumulating evidence suggests that they are localized to
various intracellular sites including nucleus, cytoplasm and
mitochondria. Recent studies have identified diverse intracellular sub-strates for MMPs and its novel biological roles.
Although the molecular mechanisms are poorly understood,
nuclear localization of MMPs has been widely observed in
various types of cells including cardiac myocytes, fibroblasts,
neuronal cells, pulmonary artery endothelial cells and hepatocytes. Currently nuclear localization of MMP-2, -3, -9,
-13 and MT1-MMP has been reported. MMP-2 and -3 have
nuclear localization sequence (NLS) in the C-terminus and
catalytic domain, respectively (Kwan et al., 2004; Si-Tayeb et
al., 2006). Nuclear localization of MMP-2 in cardiac myocytes
has been observed, highlighting its role in degradation of Poly
(ADP-ribose) polymerase (PARP) (Kwan et al., 2004). More
recently, it has been reported that cigarette-smoke induced
MMP-2 expression in the nucleus of pulmonary artery endothelial cells, causing apoptosis (Aldonyte et al., 2009). In the
ischemic neurons, increased proteolytic activity of MMP-2 and
-9 in the ischemic neuronal nuclei at the early phase is responsible for DNA fragmentation after reperfusion. This is caused
by MMP-mediated degradation of PARP-1 and X-ray crosscomplementary factor 1 (XRCC1) (Yang et al., 2010). Exclusive expression of cleaved active MMP-3 in the nucleus was
demonstrated, suggesting removal of prodomain is crucial for
nuclear translocation of MMP-3 (Si-Tayeb et al., 2006). Interestingly, transcription factor-like function of MMP-3 was shown
in chondrocytes. Binding of nuclear MMP-3 to a transcription
enhance sequence in the connective tissue growth factor
(CCN2/CTGF) enhances transcriptional activity CCN2/CTGF
(Eguchi et al., 2008). Extensive analysis of nuclear MMP-3
associated proteins (NuMAPs) identified several candidates
such as HP1γ and NCoR1 whose function on transcrip-tional
regulation of CCN2/CTGF could be modulated by MMP-3.
Nuclear localization of MMP-13 was also reported in oxygen
and glucose deprived neuronal cells and after cerebral ischemia of rats and humans (Cuadrado et al., 2009). Both MMP-2
and MT1-MMP was observed in the nuc-leus of hepatocellular carcinoma (HCC) and aggressiveness of HCC including
poor prognosis and large tumor expands was associated with
nuclear localization of MT1-MMP (Ip et al., 2007).
Increasing number of studies indicate that various MMPs
have been also found in the cytosol. We have recently demonstrated that active MMP-3 is expressed in the cytosol of dopaminergic cells and plays role in apoptosis and is involved in
cleavage of α-synuclein and DJ-1, modulating their functions
(Choi et al., 2008; Choi et al., 2011a; Choi et al., 2011b). This
will be discussed more in detail later in this review. Mitochondrial localization and perinuclear accumulation of MMP-1 was
shown in epithelial cells conferring resistance to apoptosis
(Limb et al., 2005). Intra-cellular role of MMP-2 has been highlighted in acute myocardial ischemia and reperfusion model
demonstrating that MMP-2 is responsible for cleavage of troponin I (TnI), the contractile protein regulatory element, and
the cytoskeletal protein α-actinin. Peroxynitrite is a key mediator for the activation of MMP-2 in this model (Wang et al.,
2002a; Wang et al., 2002b; Sung et al., 2007). Another example is MMP-26 which is mainly retained inside cells despite of
its N-terminal signal peptide. Prodomain of MMP-26 contains
a unique motif, PHCGVPD, that is assumed to in-crease au-
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tocatalytic activity leading intracellular activation (Marchenko
et al., 2004).

astrocytes in the brain lesions of MS patients (Cuzner et al.,
1996; Maeda and Sobel, 1996). In animal studies, the application of several MMP inhibitors elicit reduced symptoms and
severity of EAE (Hewson et al., 1995). The molecular mechanisms of MMPs in the pathogenesis of MS include the direct
destruction of myelin protein, BBB disruption and chemokine/
cytokine activation. Myelin protein could be a direct proteolytic substrate for MMPs. Activated leukocytes from peripheral
blood or CNS resident cells could release MMPs which target myelin protein resulting in fragments. Fragmented myelin
protein further activate neighboring immune cells releasing
MMPs. This forms a vicious loop for activation/destruction
leading to demyelinated axons (Starckx et al., 2003; Opdenakker et al., 2006; Candelario-Jalil et al., 2009). MMP-mediated cleavage of cytokines/chemokines and its role in immune modulation have been investigated in MS patients and
EAE model (Sellebjerg and Sørensen, 2003). MMPs are also
involved in the conversion of pro-TNF-α to mature secreted
protein and blood-brain barrier (BBB) disruption (Gearing et
al., 1994; Gasche et al., 2001).
The role of MMPs in cerebral ischemia and stroke was
also investigated both in animal mod-els and human stroke.
Dual roles of MMPs have been observed after brain ischemia:
propagat-ing neuronal death and apoptosis at the early phase
of injury through disruption of ECM and opening the BBB;
late-phase repairing by promoting angiogenesis and neurogenesis. At the early stage after stroke, transient activity of
MMP-2 which is responsible for reversible opening of the BBB
has been reported in rodent and non-human primates (Chang
et al., 2003; Yang et al., 2007). Tight junction protein, claudin-5
is degraded by MMP-2. MMP-9 is activated and implicated in
more extensive cerebral vascular damage at the later phase.
Thus, early intervention within 3 h post reperfusion with MMP
inhibitors showed the prevention of BBB disruption (Yang et
al., 2007). In addition, cerebral infarct size was significantly
reduced by treatment with MMP inhibitors or in MMP-9 knockout but not in MMP-2 knockout mice (Asahi et al., 2000; Asahi
et al., 2001). Interestingly, NO produced in cerebral ischemia
and reperfusion can activate pro-MMP-9 by S-nitrosylation
which in turn, causes direct neuronal apoptosis (Gu et al.,
2002). In reperfusion injury following ischemia in rat brain, the
expression of MMP-3 is induced in both microglia and apoptotic neurons and it is suggested that MMP-3 may play an important role in disrupting the BBB together with other MMPs
such as MMP-2 and -9 (Rosenberg et al., 2001).
Malignant gliomas are the most common malignant brain
tumors that are extremely invasive. The strong correlation between the invasiveness of glioma cells and MMPs such as
MMP-2, MMP-9 and MT-MMPs has been shown both in vitro
and in vivo (Rao et al., 1996; Uhm et al., 1996; Yamamoto
et al., 1996). The expression of MMPs are up-regulated in
many gliomas (Forsyth et al., 1999). In contrast to MMPs, the
expression of TIMP-1 and -2 is decreased, sug-gesting disruption of the balance between MMPs and their inhibitors may
contribute to pathology of malignant gliomas (Mohanam et al.,
1995). It was also shown that MMPs inhibitor induces apoptosis of malignant gliomas (Yoshida et al., 2003). MMP-9 plays a
key role in regulating in-vasiveness of malignant glioma cells
and invasiveness is largely attributed to the poor prognosis.
Recent study indentified miRNAs, miR-491-5p, as a direct
regulator of MMP-9 expression in U251 and U87 glioma cells,
demonstrating that miR-491-5p reduces MMP-9 expression

MMPs in the Central Nervous System (CNS)
A range of MMPs play multiple roles in the development
of the CNS, maintaining normal physiological functions, recovery after injury and the pathogenesis of brain diseases.
During development of the CNS, various MMPs and TIMPs
are expressed in various types of cells including neurons, astrocytes, oligodendrocytes and microglia, being involved in
neurogenesis, axonal guidance, angiogenesis and myelinogenesis (Cañete Soler et al., 1995; Vaillant et al., 2003; Larsen
et al., 2006). In the adult brain, MMPs are likely involved in a
range of pivotal processes like migration of neurons and glia,
synaptic plasticity, learning and memory, myelin turnover and
angiogenesis through extracellular matrix (ECM) remodeling
(Szklarczyk et al., 2002; Meighan et al., 2006; Ogier et al.,
2006; Bozdagi et al., 2007). They are also important in the
repair of adult brain after injuries such as spinal cord injury
and stroke (Larsen et al., 2003; Lee et al., 2006). The normal
functions of MMPs in the CNS were extensively discussed in
the recent review by Agrawal et al. (2008).

MMPs in Neurodegenerative diseases
Recently, an increasing amount of evidence suggests that
MMPs may play an crucial role in the pathogenesis of several neurodegenerative disorders including multiple sclerosis,
Alzheimer’s disease, Parkinson’s disease, malignant glioma,
neuroinflammation and ischemia (Forsyth et al., 1999; Lorenzl
et al., 2002; Lorenzl et al., 2003; Yong et al., 2007; CandelarioJalil et al., 2009; Choi et al., 2011b; Shin et al., 2012).
The roles for MMPs in the pathogenesis of multiple sclerosis (MS) have been widely studied. MS is a brain inflammatory
disorder demonstrating destruction of myelin sheath in the
brain and spinal cord. Infiltration of various types of peripheral immune cells such as T cell, dendritic cells and monocyte/
macrophages into the brain parenchyma accompanied with
breakdown of blood-brain barrier (BBB) are major pathologic
characteristics of MS. Upon entering in the CNS, they result
in severe destruction of myelin and axon in cooperation with
parenchymal resident cells including astrocytes and microglia.
Alterations of various MMPs like MMP-1, -2, -3, -7, -9, -12, -13,
-14 and -19 have been reported in MS. The MMPs were detected in the cerebrospinal fluid (CSF) of patients with MS or its
animal model, experimental allergic encephalomyelitis (EAE)
(Yushchenko et al., 2000; Fainardi et al., 2009). MMP-9 has
been most extensively studied among them. Enhanced expression of both MMP-7 and -9 in parenchymal macrophages
and small blood vessels were demonstrated in postmortem
human MS brain (Cossins et al., 1997). The ratio of MMP-9/
TIMP-1 in serum was elevated in relapsing-remitting MS patients and is cor-related with increase in positive MRI lesions
(Waubant et al., 1999). In EAE model, it has been shown that
MMP-9 plays a key role in BBB disruption and trafficking of
leukocytes into the brain parenchyma (Agrawal et al., 2006).
Higher level of MMP-2 in serum and CSF of MS patients was
also reported (Avolio et al., 2003; Benesová et al., 2009). The
increased expressions of MMPs were shown in microglia and
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and inhibits cellular invasion (Yan et al., 2011). Recently, other MMPs like MMP-1, -11 and -19 were appeared to be of importance for the development of high-grade astrocytic tumor
and may be promising targets for therapy (Stojic et al., 2008).
Alzheimer’s disease (AD) is the most common neurodegenerative disease that accounts for 50-80% of dementia. Pathologically, AD is characterized by gross atrophy of affected
cerebral cortex resulted from neuronal loss and synaptic degeneration. The temporal, parietal lobe and parts of the frontal
cortex and cingulate gyrus are most widely affected (Wenk,
2003). The presence of extracellular amyloid plaques and
intracellular neurofibrillary tangles is the most charac-teristic
pathologic feature of AD (Tiraboschi et al., 2004). Extracellular
plaques consist of about 40 amino-acid long small peptides
called beta-amyloid (Aβ). Aβ is generated by enzymatic cleavage of amyloid precursor protein (APP), a transmembrane
protein. The process involved in proteolytic cleavage of APP
is still waiting for elucidation. One of these fragments, Aβ142, gives rise to fibrils of Aβ, which further aggregates outside
neurons in dense masses of protein known as senile plaques
(Ohnishi and Takano, 2004; Tiraboschi et al., 2004). It has
been shown that MMPs play a dual role in the pathogenesis of
AD. MMPs may directly de-grade Aβ resulting in reduction in
Aβ deposit (Yan et al., 2006; Miners et al., 2008). On the other
hand, MMPs such as MMP-2, -3 and -9 could be induced by
Aβ in microglia, astrocytes or vas-cular smooth muscle cells
contributing to brain parenchymal destruction. MMP-9 is overexpressed in AD brain tissue compared to controls and it can
degrade synthetic 40-residue long Aβ protein in vitro (Backstrom et al., 1992; Roher et al., 1994). MMP-2 has also been
shown to degrade 40- to 42-residue long Aβ purified from AD
brain tissue (Roher et al., 1994). In AD brains, MMP-3 is expressed predominantly in brain white matter. Double immunostaining of MMP-3 and GFAP in the white matter suggests
that astrocytes may be a major source of MMP-3 in AD brain
(Yoshiyama et al., 2000). MMP-3 immunoreactivity was also
detected in the interstitium between myelinated axons and senile plaques of patients with AD (Yoshiyama et al., 2000). It
has been also demonstrated that Aβ1-42 induces MMP-3, -12
and -13 expressions in microglia in PI3K-dependent manner
(Ito et al., 2007). Recent analysis of CSF from AD patients
indicated that MMP-3 is significantly elevated while MMP-2
is decreased (Horstmann et al., 2010). These data suggest
that MMPs may be involved in the processing of APP and the
pathogenesis of AD.
Parkinson’s disease (PD) is the second most common neurodegenerative disorders characterized by motor symptoms
including resting tremor, rigidity, bradykinesia and postural instability resulting from selective degeneration of dopaminergic
neurons in the substantia nigra pars compacta. Accumulating
evidence suggests MMPs as a major culprit in the pathogenesis of PD. Expression of MMPs such as MMP-1, -2 and -9 as
well as TIMP-1 and -2 in the substantia nigra (SN) of postmortem PD brain tissue was first reported by Lorenzl et al. showing alterations in MMP-2 and TIMP-1 in the SN of PD patients
(Lorenzl et al., 2002). Since then, a number of studies including our own have demonstrated that MMPs are implicated in a
range of pathophysiological processes of PD such as microglial activation, inflammation, direct dopaminergic apopto-sis,
disruption of the BBB and modulation of α-synuclein pathology by cleavage (Kim et al., 2005; Choi et al., 2008; Joo et al.,
2010; Kim and Hwang, 2011).

MMP-3 was first noted as a neutral proteinase in human
cartilage in 1974 (Sapolsky et al., 1974) and in rabbit bone
fibroblast culture (Werb and Reynolds, 1974). The name
‘stromelysin’ was introduced by Chin et al. (1985), but it has
also been named ‘transin’ and ‘collagenase activating protein’ (Chin et al., 1985; Matrisian et al., 1985; Treadwell et al.,
1986). MMP-3 has a broad spectrum of substrates such as
collagens, gelatin, elastin, laminin, casein, fibronectin, α1-AT,
MBP and TNF-α precursor (Chandler et al., 1997). In addition,
MMP-3 also can play a central role in the cleavage of other
pro-form of MMPs including MMP-1, -2, -7, -8, -9, -13 leading
to active forms (Chandler et al., 1997). MMP-3 has been implicated in inflammatory dis-orders including rheumatoid arthritis
(RA), multiple sclerosis and AD (Zucker et al., 1994; Maeda
and Sobel, 1996; Yoshiyama et al., 2000). MMP-3 levels are
significantly in-creased both in serum and synovial fluid in RA
patients (Zucker et al., 1994; Ishiguro et al., 1996). Serum
MMP-3 levels are decreased by anti-TNF-α therapy in RA,
suggesting that TNF-α may induce MMP-3 expression (Catrina et al., 2002). It has also been shown that MMP-3 levels in
synovial fluid (SF) are significantly related with the concentration of soluble FasL (sFasL) in SF of patients with RA, which
indicates that MMP-3 may regulate the shedding of FasL
(Matsuno et al., 2001). The role of MMP-3 as a mediator of
neuroinflammation responsible for dopaminergic neuronal degeneration was demonstrated. Active MMP-3 is released from
neurons undergoing apoptosis after stress. Then it activates
microglia to secrete pro-inflammatory cytokines such as IL1β, TNF-α and IL-6 as well as reactive oxygen species (ROS)
that subsequently cause neighboring neuronal death. NNGH,
a specific inhibitor of MMP-3, largely attenuates microglial
activation and neuronal death (Kim et al., 2005). MMP-3 is
also involved in LPS-mediated microglial activation. MMP-3
and -9 are responsible for mitogen-activated protein kinases
(MAPKs)- and NF-κB-mediated proinflammatory cytokines release from LPS-stimulated microglia (Woo et al., 2008).
Expression and activity of MMP-3 have been shown in a
range of rodent PD models and postmortem PD brain. Increase in MMP-3 expression in the SN was observed in rodent model of PD, rats injected with 6-hydroxydopamine (6OHDA) (Sung et al., 2005). Recent study showed that MMP-3
is expressed in Lewy bodies (LBs), a pathologic hallmark of
PD (Choi et al., 2011b). Increased immunoreactivity of MMP-3
was also observed in tyrosine hydroxylase (TH)-positive dopaminergic neurons in the SN of mice administered with MPTP
(1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a selective dopaminergic neurotoxin. In this study, significant reductions in
MPTP-mediated dopaminergic neuronal degeneration as well
as microglial activation were observed in MMP-3 knockout
mice suggesting that MMP-3 is a key player in dopaminergic neuronal degeneration (Kim et al., 2007). Rat injected with
LPS in the SN shows microglial acti-vation and dopaminergic
neuronal degeneration. In this model, MMP-3 expression in
the SN was significantly increased 24 h and 48 h after LPS injection (McClain et al., 2009). In contrary to the general belief
that the inactive proform of MMP3 is activated in extracellular
space, emerging evidence implies the existence of a mechanism of intracellular activation of MMP-3. Under apoptotic
stress, MMP-3 is induced and generates the proform which
is subsequently cleaved to the catalytically active MMP-3 by a
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serine protease other than furin. Intracellular enzymatic activity of MMP-3 is directly responsible for apoptosis of dopaminergic cells (Choi et al., 2008). Recently, intracellular targets
for MMP-3 that are clearly linked to the pathogenesis of PD
have been investigated (Sung et al., 2005; Choi et al., 2011a;
Choi et al., 2011b). Mutations in SNCA that encodes α-synuclein were the first reported genetic cause in familiar forms of
PD (Polymeropoulos et al., 1997). Later, α-synuclein aggregates were identified as the major com-ponent in Lewy bodies
(LB), intracellular protein inclusions, a pathologic hallmark of
PD (Spillantini et al., 1997). α-synuclein is cleaved by MMP3 generating fragmented peptides that forms more toxic aggregates than the intact α-synuclein. MMP3-cleaved species
(N-terminal) in extra-cellular space were cytotoxic when they
were added to the cell culture media (Sung et al., 2005). The
presence of C-terminally truncated α-synuclein has been reported in Lewy bodies of sporadic PD and Lewy body dementia (Baba et al., 1998; Liu et al., 2005). C-terminal truncation
is also observed preferentially in A53T transgenic mice showing motor symptoms (Lee et al., 2002). Various lengths of the
truncated forms of α-synuclein were reported (Li et al., 2005;
Liu et al., 2005). About 15% of α-synuclein in Lewy bodies is
truncated forms and incomplete degradation produced highly

amyloidogenic fragments (Baba et al., 1998; Campbell et al.,
2001). More recently, it has been shown that MMP-3 cleaves
WT and mutant α-synuclein generating slightly different fragmented peptide profiles. MMP-3 gives rise to C-terminally
truncated peptides of amino acids 1-78, 1-91, and 1-93 and
that A53T mutant α-synuclein generates significant in-crease
of these peptides. Both in vivo and in vitro experiments shows
that these peptides cause stronger dopaminergic neuronal
death compared to the intact α-synuclein despite less aggregation formation (Choi et al., 2011b). The results suggest that
MMP-3 could modulate the aggrega-tion property of α-synuclein contributing to the pathogenesis of PD. In addition, DJ-1
is also fragmented by MMP-3. DJ-1 is a protein belonging
to ThiJ/PfpI/DJ-1 superfamily. Two mutations were identified
within the DJ-1 gene in two families linked to the recessive
PD PARK7 locus (Bonifati et al., 2003). One is a chromosomal
deletion of 4 kb leading to the absence of DJ-1 expression,
while the other is a L166P point mutation in which a highly
conserved leucine was substituted for a proline. The latter destabilizes DJ-1 protein and promotes its degradation through
the ubiquitin-proteasomal system (Miller et al., 2003). Active
MMP-3 cleaves DJ-1 caus-ing impairment of its antioxidant
function. While MPTP administration significantly diminished

Fig. 2. The role of MMP-3 in the pathogenesis of Parkinson’s disease. Emerging evidence suggests that MMP-3 plays a key role in dopa-

minergic neuronal degenera-tion. Under stress conditions, MMP-3 is induced in dopaminergic neurons generating proMMP-3. Activation of
MMP-3 might be achieved in cytoplasm as well as extracellular space. Catalytically active MMP-3 (actMMP-3) triggers microglial activation
resulting in release of proinflammatory cytokine such as IL-1β, TNF-α and IL-6. Microglial substrates for act MMP-3 and signaling event
leading to microglial activation are yet to be elucidated. NADPH oxidase (NOX2)-mediated ROS generation was also observed in microglia treated with actMMP-3. In addition, MMP-3 could be also activated intracellularly by unknown serine proteases upon stress such as
6-OHDA or MPP+, a selective dopaminergic toxin. Activated MMP-3 could cleave α-synuclein into several fragments by C-terminal truncation. These fragmented peptides are prone to aggregate and re-sult in increased cytotoxicity. MMP-3 could also degrade DJ-1 and impair its
antioxidant function resulting in increased oxidative stress. Intracellular actMMP-3 is directly linked apoptotic path-way in dopaminergic cells
as well.
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DJ-1 expression in the SN of mice, its degradation was largely
attenuated in MMP-3 knockout mice. This study suggests that
cleavage of DJ-1 by the intracellular MMP-3 in response to
cell stress impairs the protective role of DJ-1 against oxidative
damage (Choi et al., 2011a). The proposed roles of MMP-3 in
the pathogenesis of PD is illustrated in Fig. 2.

dementia, meningitis, Guillain-Barre syndrome and stroke. Of
these, MMP inhibitors have been most intensively tested in
acute cerebral ischemia. Studies on mo-noclonal antibodies
against MMPs and broad spectrum MMP inhibitors such as
GM-6001, BB-94 and BB-1101 demonstrate that BBB damage,
infarct volume and neuronal death are significantly reduced by
MMP inhibitions (Romanic et al., 1998; Gu et al., 2005). As
discussed, MMPs have a dual role after stroke, aggravating
neuronal damage at the early phase and tissue repair at the
later stage, suggesting that short-term administration during
the early stage would be effective. Patients with MS treated
with minocycline, tetracycline derivative, demonstrate reduced
number of gadolinium-enhancing lesions on MRI (Metz et al.,
2004). In EAE, MMP inhibitors reduce damage to the BBB and
low-dose tetracycline administration with interferon-beta effectively reduces inflammation (Giuliani et al., 2005). In vascular
cognitive impairment which is charac-terized by progressive
white matter damage cause by ischemic injury or hypoxic
hypoperfusion, MMP inhibitors reduce white matter damage
(Cho et al., 2006; Walker and Rosenberg, 2010). Use of MMP
inhibitors in the treatment of AD is controversial since they are
involved in the genera-tion of Aβ from APP as well as clearance of Aβ As discussed earlier, a couple of MMPs, especially
MMP-3, play crucial roles in the pathogenesis of PD, suggesting that MMP inhibitors might ameliorate dopaminergic neuronal degeneration.

MMP inhibitors and Neuronal disorders
As emerging evidence indicates MMPs as a major culprit
for a number of disease conditions including cancers, inflammation and neurodegenerative disorders, the importance of
MMPs as a therapeutic target has been highlighted. MMP inhibitors could be categorized into two groups, macromolecular
inhibitors such as TIMPs and monoclonal antibodies and small
molecules including natural and synthetic inhibitors (Sang et
al., 2006; Hu et al., 2007). TIMPs are the most thoroughly studied natural MMP inhibitors. Physiological balance between
MMPs and TIMPs are considered important to prevent multiple disease conditions. Long-chain fatty acids, epigal-locatechin gallate (EGCG) extracted from green tea and flavonoids
also belong to natural MMP inhibitors. Since the first endeavor
to develop smallmolecule MMP inhibitors for the treatment of
arthritis, a number of synthetic MMP inhibitors have been tested for various diseases over the past three decades. The first
generation of synthetic MMP inhibitors was designed based
on mimicking natural peptide substrates, thus so called peptidomimetic MMP inhibitors. Later on, structure-based MMP
inhibitors with a zinc-binding group (ZBG), a backbone that
chelates zinc ion in the catalytic core of MMPs, have been
extensively developed and tested. Four major ZBGs have
been exploited for the development of MMP inhibitors: carboxylates, thiolates, phosphinyls and hydroxamates. Of these,
hydroxamates-based MMP inhibitors have been stu-died most
widely. A ZBG of hyroxamate acts as a bidentate ligand with
the catalytic zinc ion and it also forms hydrogen bonds with
enzyme backbones, resulting in potent inhibitory effect. Batimastat is one of the first generation of broad-spectrum hydroxamates inhibitors. Because of the similarity of catalytic core
structure between MMPs, it has been challenging to develop
highlyselective MMP inhibitors. As crystallographic structures
of more MMPs were revealed, the nextgeneration MMP inhibitors with greater target selectivity were designed. Prinomastat
is a second-generation hydroxamates MMP inhibitor that has
much higher IC50 value against MMP-1 and -7 (Sang et al.,
2006). Due to their numerous normal physiological functions
including tissue remodeling, repression of tumor angiogenesis and inactivation of chemokines, therapeutic inhi-bitions
of MMPs have potential to accompany side effects. Musculoskeletal syndrome (MSS) is the most common side effect
caused by many MMP inhibitors, which is characterized by
joint pain, stiffness and tendinitis (Cho et al., 2006). Despite
the effort toward developing MMP inhibi-tors with high selectivity and therapeutic efficacy, tetracycline derivative, doxycycline, remains the only FDA approved MMP inhibitor (Hu et al.,
2007). In spite of their low potency, non-hydroxamates MMP
inhibitors containing other ZBGs such as carboxylates with
greater target specificity have been developed (Walker and
Rosenberg, 2010).
It has been reported that MMP inhibitors bring about beneficial effects in animal studies of multiple sclerosis, vascular

CONCLUSION
In this review, we discuss general structure, activation, regulation and functions of MMPs and subtilize their roles in the
CNS. Finally, we emphasize on the implication of MMPs in a
range of neurodegenerative conditions. Based on an increasing number of studies, we further discuss the link between
MMP-3 and the pathogenesis of PD. Lastly, current status on
development of MMP inhibitors for treatment of neurodegenerative diseases is discussed. We are anticipating much more
exciting works that potentially lead to therapeutic interventions
for various brain disorders.
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